The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04842019
Recruitment Status : Active, not recruiting
First Posted : April 12, 2021
Last Update Posted : April 11, 2023
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Co., Ltd.

Brief Summary:
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with XLH

Condition or disease Intervention/treatment Phase
X-linked Hypophosphatemia (XLH) Drug: KRN23 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Actual Study Start Date : September 28, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023


Arm Intervention/treatment
Experimental: KRN23
KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks for 48 weeks. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
Drug: KRN23
KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Other Names:
  • Burosumab
  • Crysvita




Primary Outcome Measures :
  1. Change from Baseline (CFB) in mean serum phosphorus level at the end of the dose cycle [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 36, and 48 ]

Secondary Outcome Measures :
  1. Change in Brief Pain Inventory (BPI) Worst Pain score over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
    Change from baseline to post-baseline visits in BPI-Q3 (Worst Pain) score as averaged from daily diary scores recorded over 1 week and the study visit score. The BPI evaluates the condition of all pain over the previous 24 hours. Two dimensions are measured: pain severity (worst, least, average, and now) and the impact of pain on functioning (pain interference with general activity, walking, work, mood, enjoyment of life, relations with others, and sleep). Question 3 of the short-form BPI (BPI-Q3) asks subjects to rate their pain at its worst in the last 24 hours on a scale of 0 (no pain) to 10 (pain as bad as you can imagine).

  2. Change in BPI Pain Severity score and Pain Interference score over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
    Change from baseline to post-baseline visits in BPI pain severity score as averaged from daily diary scores recorded over 1 week and the study visit score. The BPI evaluates the condition of all pain over the previous 24 hours. Two dimensions are measured: pain severity (worst, least, average, and now) and the impact of pain on functioning (pain interference with general activity, walking, work, mood, enjoyment of life, relations with others, and sleep). The severity of pain in the last 24 hours is rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine).

  3. Change in BPI Pain Interference score over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
    Change from baseline to post-baseline visits in BPI pain interference score as recorded on the day of the study visit. The BPI evaluates the condition of all pain over the previous 24 hours. Two dimensions are measured: pain severity (worst, least, average, and now) and the impact of pain on functioning (pain interference with general activity, walking, work, mood, enjoyment of life, relations with others, and sleep). Pain interference in the last 24 hours is rated on a scale of 0 (does not interfere) to 10 (completely interferes).

  4. Change in the Stiffness and Physical Function domains of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
    The WOMAC is a 24-item participant-reported questionnaire with two domains, Stiffness (2 questions) and Physical Function (17 questions) over the previous 48 hours. The WOMAC is administered in a 5-point Likert-scale format using descriptors of none, mild, moderate, severe, and extreme corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse stiffness and functional limitations. Scores are normalized to a 0-100 metric where 0 was the best health state and 100 the worst.

  5. Change in the health related QOL assessment by Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
    The PROMIS was developed by the National Institutes of Health and uses domain-specific measures to assess patient well-being (Broderick et al. 2013), (NIH 2015). It uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. For the Physical Function Domain, increases indicate greater mobility.

  6. The proportion of subjects achieving mean serum phosphorus levels above the lower limit of normal (LLN; 2.5 mg/dL [0.81 mmol/L]) at the end of the dosing cycle [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 36, and 48 ]
  7. The proportion of subjects achieving mean serum phosphorus levels above the LLN (2.5 mg/dL [0.81 mmol/L]) at the mid-point of dosing cycle [ Time Frame: Weeks 2, 6, 10, 14, 18 and 22 ]
  8. CFB in mean serum phosphorus level at the mid-time point of dosing cycle [ Time Frame: Weeks 2, 6, 10, 14, 18 and 22 ]
  9. Mean percent CFB in serum phosphorus levels averaged at the end of dose cycles [ Time Frame: Baseline to Week 48 ]
  10. Cumulative exposure: area under curve (AUC) of serum phosphorus [ Time Frame: Baseline to Week 48 ]
  11. Change in serum 1,25(OH)2D over time [ Time Frame: Baseline to Week 48 ]
  12. Change in urinary phosphorus over time [ Time Frame: Baseline to Week 48 ]
  13. Change in ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR; algorithm method) over time [ Time Frame: Baseline to Week 48 ]

Other Outcome Measures:
  1. Radiologic healing or resolution of pre-existing fractures and/or pseudofractures, as defined by skeletal survey at Baseline and subsequent targeted radiography [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
  2. Change in enthesopathy spur at the calcaneus measured by lateral foot X-rays [ Time Frame: Weeks 0, 24 and 48 ]
  3. Change in 6-minute walking test (6MWT) over time [ Time Frame: Weeks 0, 12, 24, 36, and 48 ]
  4. Safety of KRN23 by studying the number, severity and relatedness of Adverse Events (including laboratory and imaging assessments) [ Time Frame: Week 0 to Week 56 ]
    Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments as well as ECHO, ECG, ultrasound, vital sign, X-Ray images and Anti-KRN23 antibody.

  5. Pharmacokinetics: KRN23 concentrations [ Time Frame: Week 0, 1, 2, 4, 21, 22, 24, 36, 48 and 56 ]
    KRN23 concentration in the Mid and end of dose cycles.

  6. Change from Week -14 to Baseline in serum phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  7. Percent change from Week -14 to Baseline in serum phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  8. Change from Week -14 to Baseline in serum 1,25(OH)2D over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  9. Percent change from Week -14 to Baseline in serum 1,25(OH)2D over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  10. Change from Week -14 to Baseline in plamas iPTH over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  11. Percent change from Week -14 to Baseline in plamas iPTH over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  12. Change from Week -14 to Baseline in serum calcium over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  13. Percent change from Week -14 to Baseline in serum calcium over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  14. Change from Week -14 to Baseline in urinary phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  15. Percent change from Week -14 to Baseline in urinary phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  16. Change from Week -14 to Baseline in TmP/GFR over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  17. Percent change from Week -14 to Baseline in TmP/GFR over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  18. Safety of conventional therapy by studying the number, severity and relatedness of Adverse Events [ Time Frame: Week -14 to Week 0 ]
    Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments during Run-in period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female Chinese patients, aged 18 to 65 years (inclusive) at the time of signing the ICF
  2. Diagnosis of XLH supported by classic clinical features of adult XLH (such as short stature or bowed legs) and at least either of the following at screening:

    • Confirmed PHEX mutation (prior to the study with historic record) in the patient or a directly related family member with appropriate X linked inheritance
    • Serum iFGF23 level ≥30 pg/mL by the Kainos assay at Screening
  3. Biochemical findings consistent with XLH following overnight fasting (≥8 hours) at Screening:

    • Serum phosphorus <2.5 mg/dL (0.81 mmol/L). Serum phosphorus level may be re tested (once only) at least 7 days after discontinuation of therapy, if applicable.
    • TmP/GFR of <2.5 mg/dL
  4. Presence of skeletal pain attributed to XLH/osteomalacia, as defined by a score of ≥4 on the BPI Worst Pain question at Screening (Skeletal pain that, in the opinion of the investigator or subinvestigator, is attributed solely to causes other than XLH/osteomalacia [e.g., back pain or joint pain in the presence of severe osteoarthritis by radiograph in that anatomical location] in the absence of any skeletal pain likely attributed to XLH/osteomalacia should not be considered for eligibility)
  5. Patients who are taking chronic pain medications (including narcotic pain medications/opioids) must be on a stable regimen for at least 21 days before signing the ICF and be willing to maintain the medications at the same stable dose(s) and schedule throughout the study. The dose must not exceed 60 mg oral morphine equivalents/day
  6. Able to receive conventional therapy (oral phosphate and pharmacologic vitamin D [or metabolites/analogs])
  7. Written informed consent provided after the nature of the study has been explained and prior to any research related procedures
  8. Willing to provide access to prior medical records for the collection of biochemical and radiographic data and disease history
  9. Have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study (female patients of child-bearing potential only)
  10. Be willing to use an effective method of contraception while participating in the study (sexually active patients of child bearing potential) and for 12 weeks after last dose of study drug. Women of non child bearing potential are defined as permanently sterile (i.e. due to hysterectomy or bilateral oophorectomy) or postmenopausal (defined as at least 12 months postcessation of menses without an alternative medical cause). Postmenopausal status of female patients will be confirmed with a Screening serum follicle stimulating hormone (FSH) level >40 mIU/mL
  11. Be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments, as judged by the investigator or subinvestigator
  12. Have completed entries for ≥4 of 7 consecutive days of the patient diaries before Week -14

Exclusion Criteria:

  1. Use of a pharmacologic vitamin D, its metabolites, or analogs, and oral phosphate for treatment of XLH within 14 days prior to Screening.
  2. Use of aluminum hydroxide antacids, acetazolamide, thiazide diuretics and/or systemic corticosteroids within 14 days prior to Week -14
  3. Corrected serum calcium level ≥10.8 mg/dL (2.69 mmol/L) at Screening
  4. Plasma iPTH ≥2.5 times the upper limit of normal at Screening
  5. Uncontrolled diabetes mellitus, defined as HbA1c >7.5% at Screening
  6. Use of medication to suppress PTH (e.g., Sensipar®, cinacalcet, calcimimetics) within 60 days before signing the ICF
  7. Use of oral bisphosphonates in the 2 years before signing the ICF
  8. Planned or recommended orthopedic surgery within the clinical trial period
  9. History of traumatic fracture or orthopedic surgery within 6 months before signing the ICF
  10. Use of KRN23, or any other therapeutic mAb within 90 days before signing the ICF
  11. Use of any investigational product or investigational medical device within 30 days before signing the ICF, or requirement for any investigational agent prior to completion of all scheduled study assessments
  12. Pregnant or breastfeeding at Screening or Week -14, or intention to become pregnant (the patient or partner) at any time during the study
  13. Unable or unwilling to withhold prohibited medications throughout the study
  14. Presence or history of any hypersensitivity, or allergic or anaphylactic reactions to any mAb or KRN23 excipients that, in the judgment of the investigator or subinvestigator, places the patient at increased risk for adverse effects
  15. Positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibody at Screening, or prior history of positive test
  16. History of recurrent infection or predisposition to infection, or of known immunodeficiency
  17. Presence of malignant neoplasm (except basal cell carcinoma)
  18. Presence of a concurrent disease or condition that would interfere with study participation or affect safety
  19. Presence or history of any condition that, in the view of the investigator or subinvestigator, places the patient at high risk of poor treatment compliance or of not completing the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04842019


Locations
Layout table for location information
China
Peking Union Medical College Hospital
Beijing, China
The First Medical Center of Chinese People's Liberation Army General Hospital
Beijing, China
Nanfang Hospital
Guangzhou, China
The Second Affiliated Hospital of Zhejiang University
Hangzhou, China
Shanghai 6th Hospital
Shanghai, China
Sponsors and Collaborators
Kyowa Kirin Co., Ltd.
Layout table for additonal information
Responsible Party: Kyowa Kirin Co., Ltd.
ClinicalTrials.gov Identifier: NCT04842019    
Other Study ID Numbers: KRN23-CN005
CTR20210506 ( Other Identifier: www.chinadrugtrials.org.cn )
First Posted: April 12, 2021    Key Record Dates
Last Update Posted: April 11, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Hypophosphatemic Rickets
Hypophosphatemia
Phosphorus Metabolism Disorders
Metabolic Diseases
Rickets, Hypophosphatemic
Rickets
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Hypophosphatemia, Familial
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Male Urogenital Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Calcium Metabolism Disorders
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders